More data supported links between the erectile dysfunction drug sildenafil (Viagra) and reduced Alzheimer’s risk. (Journal of Alzheimer’s Disease)
The American Headache Society issued a consensus position statement saying drugs targeting calcitonin gene-related peptide are a first-line option for migraine prevention. (Headache)
Eli Lilly said the FDA will hold an advisory committee meeting to discuss the phase III TRAILBLAZER-ALZ 2 trial of investigational donanemab in early symptomatic Alzheimer’s disease.
Glial fibrillary acid protein and neurofilament heavy chain in cerebrospinal fluid were associated with non-relapsing MS. (JAMA Neurology)
A recently approved combination of sodium phenylbutyrate and taurursodiol (Relyvrio) did not meet its primary endpoint in a confirmatory amyotrophic lateral sclerosis trial, Amylyx Pharmaceuticals said. The company may pull the drug from the market.
Cysticercosis — infection caused by tapeworm larvae — presented as migraine in a 52-year-old man. (American Journal of Case Reports)
Merck KGaA dropped its investigational Bruton’s tyrosine kinase (BTK) inhibitor evobrutinib after the drug failed to beat teriflunomide (Aubagio) in two phase III trials of multiple sclerosis. (Fierce Biotech)
The FDA updated its draft guidance for developing drugs to treat early Alzheimer’s disease to include the agency’s current thinking about biomarkers in clinical trials.
Functional MRI showed how the brain focused on paying attention while filtering distraction. (Nature Human Behavior)
Nearly half of patients who used cannabis to manage migraine said it contributed to using less migraine medication. (Neurology)
Please enable JavaScript to view the